REMEDI Philippines OPC · Company Brief
Bringing diagnostics
to
where care can’t reach
A medtech company improving healthcare access across the Philippines with AI-enabled ultraportable diagnostics — from early TB detection to mobile diagnostic networks, working alongside the Department of Health toward equitable healthcare.
RemediPH : Sale & Marketing
PortaMed : A/S, Tech Support, System Integration
— Website : portamed.com.ph
20M+
Filipinos in GIDA areas lacking diagnostic access
81
provinces targeted for nationwide scale-up
4
core business areas at REMEDI
Mobile Diagnostic Van — Health Centrum Hospital x KOICA x REMEDI
Who We Are
Practical diagnostic innovation for Universal Health Care
REMEDI Philippines OPC is a medical technology company based in Bonifacio Global City (BGC), Taguig. We support the Philippine healthcare system through innovative diagnostic technologies that improve access to early disease detection, particularly in geographically isolated and disadvantaged areas (GIDA).
We combine portable medical devices, artificial intelligence, and digital health technologies to strengthen primary healthcare and support Universal Health Care (UHC).
Our Mission
“To make high-quality diagnostic imaging accessible to every Filipino — by combining portable medical devices, artificial intelligence, and digital health technologies.”
Core Business Areas
REMEDI Philippines’ Four Core Competencies
From portable imaging hardware to AI interpretation, mobile diagnostic networks, and field-based active case finding — connecting every moment a diagnosis is needed.
Ultraportable Chest X-ray
AI-enabled ultraportable chest X-ray solutions integrated with WHO-aligned computer-aided detection (CAD), enabling rapid, high-quality chest imaging for TB screening and other pulmonary diseases where conventional radiology is out of reach.
AI-Assisted Diagnostic Imaging
AI-assisted interpretation linked with real-time EMR and teleradiology, extending urban-grade diagnostic accuracy to remote and island communities.
Mobile Diagnostic Network
Mobile Diagnostic Vans and Trucks that bring hospital-grade diagnostics — X-ray, TB molecular testing, HIV screening, breast cancer screening — directly to the barangay level.
Active Case Finding
Community-based active TB case finding in partnership with the Philippine Tuberculosis Society (PTSI), proving the value of field-deployed portable imaging.
AI Diagnostics · Imaging Modalities
Two imaging modalities, AI-assisted at the point of care
Every UPXR and MDA exam is paired with computer-aided detection before it reaches a physician — prioritizing urgent findings, supporting non-radiologist readers, and keeping screening throughput high even where no on-site radiologist is available.
1. Chest X-Ray (CXR)
JLK — Korean CAD platform for chest radiograph triage and abnormality detection.
Deeptek — teleradiology-integrated AI reader for chest X-ray reporting workflows.
Lunit INSIGHT CXR — WHO-recognized CAD engine with a dedicated tuberculosis-screening module, used across national TB programs worldwide.
2. Mammography (MMG)
Lunit is REMEDI’s mammography AI partner — reading 2D and 3D breast tomosynthesis exams from the MDT-1 mobile mammography unit, with density assessment and lesion-level scoring built in.
Standalone accuracy
~96% AUROC
Reading time
-36% on 2D mammograms
Density grading
BI-RADS A–D
Certification
CE Marked, FDA Cleared
TB SCREENING TRACK RECORD
40+
Lunit INSIGHT CXR is named in the WHO policy statement on computer-aided TB detection and is commercially deployed across 40+ countries, including national screening programs in Korea, Indonesia, and the Philippines.
BREAST SCREENING VALIDATION
130+
In BreastScreen NSW’s Australia-wide rollout, Lunit’s machine-reading technology flagged over 130 cancers in its first year and is projected to cut recall callbacks by roughly 20%.
UPXR — THE REMEX-KA6 PLATFORM
The handheld X-ray behind REMEDI’s TB screening work
REMEDI’s ultraportable chest X-ray platform is built around the REMEX-KA6 handheld X-ray camera — the same generation of device REMEDI has deployed at national scale for tuberculosis screening programs, brought to the point of care instead of the other way around.
Low Dose
Engineered to minimize radiation exposure for both patients and operators, increasing X-ray efficiency while reducing the dose generated per exposure.
High Resolution
Proprietary imaging technology paired with advanced image processing delivers diagnostic-grade clarity — image acquisition in under 3 seconds.
Light Weight
A compact, handheld form factor with no fixed installation required — full portability with no location constraints.
Performance & Specifications
Tube Voltage
40 – 70 kV (variable)
Tube Current
2 – 6 mA (variable)
Exposure Time
0.06 – 2.0 sec
Focal Spot
0.4 mm
Nominal Power
420 W (70kV, 6mA, 0.1s)
Dimensions
165.3 × 176.0 × 255.6 mm
Weight
2.4 kg
Battery
DC 22.2V / 1,800 mAh
Covers chest, pelvis, abdomen, hand, foot, and head imaging — paired with AI-assisted interpretation and WHO-aligned CAD for TB screening workflows.
PROVEN IN INDIA
1,534+
REMEX-KA6 units supplied through Indian government tuberculosis-screening tenders, including a national contract with the Indian TB Association and an additional order of roughly 750 units — one of the largest portable X-ray deployments in a national TB program to date.
EVALUATED BY NASA
1 of 3
The REMEX-KA6 was selected as one of three candidate compact X-ray systems — alongside MinXray Impact and FujiFilm Xair — for NASA’s Exploration Medical Capability ground demonstration study evaluating portable radiography for future deep-space missions. REMEDI has also reported that its ultra-compact Xcam6 was selected as a flight-test device for astronaut imaging aboard a SpaceX crewed mission.
Sources: NASA Technical Reports Server (NTRS); REMEDI Inc. company news and IPO disclosures.
MDA · Mobile Diagnostic Network
Hospital-grade diagnostics, down to the barangay
A nationally coordinated mobile diagnostic program led by Health Centrum Hospital, the KOICA Inclusive Business Program (IBS), and REMEDI Company. Instead of patients traveling to services, diagnostics travel to the patients.
Mobile Diagnostic Van (MDV) — fully electric, satellite-connected
Mobile Diagnostic Truck (MDT-1) — with 3D mammography
Mobile Diagnostic Tricycle — for last-mile barangay access
Onboard Equipment
- 1× 100kVp portable digital X-ray (primary) + 1× 70kVp ultraportable X-ray (supplemental), full lead shielding on all vehicles
- GeneXpert Omni rapid TB molecular diagnostics
- HIV rapid testing station
- Point-of-care laboratory suite — CBC, urinalysis, fasting blood sugar
- 12-lead ECG, portable ultrasound, newborn hearing screener (AOAE)
- Digital stethoscope and spirometer
- Starlink satellite connectivity, real-time EMR, AI-assisted interpretation, PhilHealth eClaims integration
- MDT-1 exclusive: portable 3D mammography machine for mobile breast cancer screening nationwide
3
Region VI pilot units (2 MDVs + 1 MDT)
200+
mobile diagnostic units targeted nationwide
2027
full operations begin (after Oct. 2026 inception phase)
ACF — Active Case Finding
Field-proven experience in TB control
REMEDI Philippines has worked closely with the Philippine Tuberculosis Society, Inc. (PTSI) to support active TB case-finding initiatives. Through field implementation, our portable imaging solutions have demonstrated real value in community-based screening and outreach programs.
Dr. Camilo Roa Jr.
President, PTSI
Dr. Paulyn Jean Rosell-Ubial
Executive Director, PTSI
Field Impact
Community-based TB screening
On-site screening combining UPXR with AI interpretation has demonstrated that TB and pulmonary disease screening is achievable even where radiology infrastructure is absent. This experience directly informs the TB molecular diagnostics (GeneXpert Omni) built into the MDA mobile diagnostic program.
Areas of Collaboration with DOH
Collaboration with the Department of Health
01
Active TB case finding and screening
02
Mobile and community-based diagnostic services
03
AI-assisted diagnostic imaging
04
Digital health and teleradiology
05
Primary healthcare strengthening in GIDA communities
06
Capacity building and technology transfer